vs

Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and GoHealth, Inc. (GOCO). Click either name above to swap in a different company.

GoHealth, Inc. is the larger business by last-quarter revenue ($12.6M vs $9.2M, roughly 1.4× Foghorn Therapeutics Inc.). On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -96.8%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -73.9%).

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.

GoHealth, Inc. is an American marketplace for Medicare plans including Medicare Advantage, MediGap and Medicare Part D, which are programs administered through private health insurance companies. It also operates an online health insurance marketplace offering individual health insurance and short-term health insurance.

FHTX vs GOCO — Head-to-Head

Bigger by revenue
GOCO
GOCO
1.4× larger
GOCO
$12.6M
$9.2M
FHTX
Growing faster (revenue YoY)
FHTX
FHTX
+320.5% gap
FHTX
223.8%
-96.8%
GOCO
Faster 2-yr revenue CAGR
FHTX
FHTX
Annualised
FHTX
35.3%
-73.9%
GOCO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FHTX
FHTX
GOCO
GOCO
Revenue
$9.2M
$12.6M
Net Profit
$-21.7M
Gross Margin
65.6%
Operating Margin
-258.2%
Net Margin
-234.3%
Revenue YoY
223.8%
-96.8%
Net Profit YoY
-11.1%
-227.8%
EPS (diluted)
$-0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FHTX
FHTX
GOCO
GOCO
Q4 25
$9.2M
$12.6M
Q3 25
$8.2M
$34.2M
Q2 25
$7.6M
$94.0M
Q1 25
$6.0M
$221.0M
Q4 24
$2.9M
$389.1M
Q3 24
$7.8M
$118.3M
Q2 24
$6.9M
$105.9M
Q1 24
$5.0M
$185.6M
Net Profit
FHTX
FHTX
GOCO
GOCO
Q4 25
$-21.7M
Q3 25
$-15.8M
$-165.8M
Q2 25
$-17.9M
$-54.3M
Q1 25
$-18.8M
$-4.4M
Q4 24
$-19.5M
$25.5M
Q3 24
$-19.1M
$6.8M
Q2 24
$-23.0M
$-26.0M
Q1 24
$-25.0M
$-9.2M
Gross Margin
FHTX
FHTX
GOCO
GOCO
Q4 25
65.6%
Q3 25
41.2%
Q2 25
65.5%
Q1 25
82.2%
Q4 24
86.6%
Q3 24
83.4%
Q2 24
80.5%
Q1 24
79.5%
Operating Margin
FHTX
FHTX
GOCO
GOCO
Q4 25
-258.2%
Q3 25
-226.9%
-842.2%
Q2 25
-279.2%
-105.7%
Q1 25
-385.0%
3.0%
Q4 24
-840.5%
20.6%
Q3 24
-305.5%
-36.1%
Q2 24
-386.6%
-38.4%
Q1 24
-558.3%
-2.2%
Net Margin
FHTX
FHTX
GOCO
GOCO
Q4 25
-234.3%
Q3 25
-194.4%
-485.1%
Q2 25
-237.3%
-57.7%
Q1 25
-316.4%
-2.0%
Q4 24
-682.9%
6.6%
Q3 24
-244.9%
5.7%
Q2 24
-333.6%
-24.6%
Q1 24
-495.4%
-5.0%
EPS (diluted)
FHTX
FHTX
GOCO
GOCO
Q4 25
$-0.35
Q3 25
$-0.25
$-11.80
Q2 25
$-0.28
$-5.10
Q1 25
$-0.30
$-0.52
Q4 24
$-0.23
$2.62
Q3 24
$-0.31
$0.46
Q2 24
$-0.45
$-2.70
Q1 24
$-0.59
$-1.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FHTX
FHTX
GOCO
GOCO
Cash + ST InvestmentsLiquidity on hand
$80.9M
$32.9M
Total DebtLower is stronger
$636.7M
Stockholders' EquityBook value
$-108.5M
$37.9M
Total Assets
$198.1M
$987.4M
Debt / EquityLower = less leverage
16.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FHTX
FHTX
GOCO
GOCO
Q4 25
$80.9M
$32.9M
Q3 25
$89.3M
$32.1M
Q2 25
$72.6M
$35.6M
Q1 25
$61.0M
$22.2M
Q4 24
$55.5M
$40.9M
Q3 24
$57.7M
$35.5M
Q2 24
$138.9M
$14.1M
Q1 24
$79.3M
$97.8M
Total Debt
FHTX
FHTX
GOCO
GOCO
Q4 25
$636.7M
Q3 25
$581.8M
Q2 25
$560.0M
Q1 25
$485.9M
Q4 24
$487.4M
Q3 24
$481.3M
Q2 24
$453.3M
Q1 24
$485.3M
Stockholders' Equity
FHTX
FHTX
GOCO
GOCO
Q4 25
$-108.5M
$37.9M
Q3 25
$-89.7M
$68.2M
Q2 25
$-76.7M
$191.8M
Q1 25
$-61.7M
$241.6M
Q4 24
$-45.5M
$241.8M
Q3 24
$-28.3M
$212.0M
Q2 24
$-14.3M
$202.7M
Q1 24
$-97.5M
$225.9M
Total Assets
FHTX
FHTX
GOCO
GOCO
Q4 25
$198.1M
$987.4M
Q3 25
$205.0M
$1.0B
Q2 25
$226.2M
$1.3B
Q1 25
$258.7M
$1.4B
Q4 24
$284.0M
$1.5B
Q3 24
$308.4M
$1.3B
Q2 24
$328.6M
$1.3B
Q1 24
$255.0M
$1.4B
Debt / Equity
FHTX
FHTX
GOCO
GOCO
Q4 25
16.81×
Q3 25
8.54×
Q2 25
2.92×
Q1 25
2.01×
Q4 24
2.02×
Q3 24
2.27×
Q2 24
2.24×
Q1 24
2.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FHTX
FHTX
GOCO
GOCO
Operating Cash FlowLast quarter
$-22.3M
$-121.9M
Free Cash FlowOCF − Capex
$-130.2M
FCF MarginFCF / Revenue
-1030.1%
Capex IntensityCapex / Revenue
0.0%
65.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-221.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FHTX
FHTX
GOCO
GOCO
Q4 25
$-22.3M
$-121.9M
Q3 25
$-18.9M
$-32.7M
Q2 25
$-21.0M
$-37.8M
Q1 25
$-24.0M
$-12.4M
Q4 24
$-24.5M
$-21.6M
Q3 24
$-21.0M
$-12.2M
Q2 24
$-25.5M
$-36.5M
Q1 24
$-29.3M
$12.5M
Free Cash Flow
FHTX
FHTX
GOCO
GOCO
Q4 25
$-130.2M
Q3 25
$-35.0M
Q2 25
$-21.0M
$-40.6M
Q1 25
$-24.0M
$-15.5M
Q4 24
$-25.0M
$-35.3M
Q3 24
$-21.3M
$-16.5M
Q2 24
$-25.6M
$-39.2M
Q1 24
$-29.4M
$8.0M
FCF Margin
FHTX
FHTX
GOCO
GOCO
Q4 25
-1030.1%
Q3 25
-102.4%
Q2 25
-278.2%
-43.2%
Q1 25
-403.2%
-7.0%
Q4 24
-875.3%
-9.1%
Q3 24
-273.0%
-13.9%
Q2 24
-371.0%
-37.0%
Q1 24
-583.1%
4.3%
Capex Intensity
FHTX
FHTX
GOCO
GOCO
Q4 25
0.0%
65.3%
Q3 25
0.0%
6.9%
Q2 25
0.3%
3.0%
Q1 25
0.5%
1.4%
Q4 24
16.8%
3.5%
Q3 24
4.0%
3.6%
Q2 24
0.2%
2.6%
Q1 24
2.0%
2.5%
Cash Conversion
FHTX
FHTX
GOCO
GOCO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-0.85×
Q3 24
-1.80×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons